Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients

Qiuhong Shu, Liyong Wu, Ran Zhang, Qian Zhang, Jingjing Huang & Yong Meng

No previous study reports the effect of age on cardiac performance, motor function and quality of life (QoL) in Chinese chronic heart failure (CHF) patients. This single-center, prospective study enrolled CHF patients with resting heart rate (RHR) > 80 bpm, who were treated with metoprolol and were followed up at 1, 3, 6, and 12 months. Changes in cardiac, motor, and QoL parameters between patients aged ≥ 60 years and those aged < 60 years were compared at all time points. \( P < 0.05 \) was considered significant. A total of 154 patients were enrolled (median age: 66.39 years; 116 aged ≥ 60 years, 38 aged < 60 years; 95% New York Heart Association class III-IV). RHR decreased significantly in both patient groups (\( P < 0.0001 \) for both groups). Patients aged ≥ 60 years had a significant improvement in both ejection fraction (EF) at 6 and 12 months and in cardiac index (CI) at 3, 6, and 12 months. However, no major difference was observed in motor function in both groups. Significantly higher SF-8 scores showed greater improvement in QoL in the < 60 age group at 12 months (\( P = 0.0008 \)). Metoprolol demonstrated improvement in cardiac performance, motor function, QoL, and anxiety with increase in depression and burnout in both genders; however, the findings were independent of age.

Chronic heart failure (CHF) is a complex physiological syndrome caused from structural or functional alterations to the myocardium. The prognosis of CHF is closely associated with age > 40 years, comorbid conditions, and oxygen consumption. Further, CHF significantly impairs the patients’ ability to perform daily activities along with causing multiple neurological disorders including stroke and cognitive impairment. Approximately, 4.2 million people are currently affected by heart failure (HF) in China, which may be attributed to rapid change in lifestyle and industrialization. These numbers are expected to rise further due to increasing proportion of aging population and other risk factors. Despite advancements, the prognosis of HF patients have been reportedly poor and requires additional palliative care along with symptomatic control among the elderly patients with CHF.

\( \beta \)-Adrenoceptors are essential regulators of cardiovascular homeostasis. Types of \( \beta \)-adrenoceptors, namely, \( \beta \)-1 and \( \beta \)-2, are predominantly present in the heart and vascular smooth muscles, respectively. The inhibitors of \( \beta \)-adrenoceptors, that is \( \beta \)-blockers, possess vasodilating effects, which are mediated by \( \alpha \)-1 adrenoceptor blockade, \( \beta \)-2 adrenoceptor agonism, or nitric oxide synthesis. Also, \( \beta \)-blockers are competitive inhibitors of \( \beta \)-receptors and tend to inhibit the effects of catecholamine in CHF. Thus, \( \beta \)-blockers are one of the mainstays of treatment for CHF because of their ability to reverse the neurohumoral effects of the sympathetic nervous system, with ensuring symptomatic benefits by lowering heart rate (HR) and contractility, consequently lowering the mortality of CHF. The same has been demonstrated in terms of improving survival and quality of life (QoL) of CHF patients, indicating their importance in CHF management. On the contrary, administration of \( \beta \)-blockers increases the risk of depression, a key factor for deteriorating QoL and increased mortality risk among CHF patients.
According to the MERIT-HF\textsuperscript{15,24} and RESOLVD studies\textsuperscript{24}, metoprolol succinate, a cardioselective β-blocker, is one of the β-blockers recommended for preventing the incidence of death in HF patients\textsuperscript{2}. Additionally, CHF patients reported improvement in QoL in terms of physical activity, social functions and life satisfaction compared with standard therapy\textsuperscript{21} and placebo\textsuperscript{25}. Previously, only one study has reported the overall effect of metoprolol on cardiac performance, motor function, and QoL in Chinese patients\textsuperscript{26} with no separate evaluation in elderly patients. Thus, indicating the paucity of data on age-dependent cardiac, motor, and QoL outcomes of metoprolol. The present study will add insight about the risk-to-benefit ratio of metoprolol treatment in aged population. Therefore, this study was performed to compare the effect of metoprolol treatment in elderly (aged ≥60 years) and non-elderly Chinese CHF patients (aged <60 years) in terms of change in cardiac function, motor function, QoL, and mental status.

**Results**

**Baseline characteristics.** A total of 154 patients (median age 66.39 years; body mass index 23.85 ± 3.62 kg/m\(^2\); 65.5% male patients) were analyzed of the 169 patients included. Of the 154 patients, 116 were elderly (aged ≥60 years) and the remaining 38 patients were non-elderly (aged <60 years) (Fig. 1). At baseline, family history of cardiac disease and hypertension were reported in 35.0% and 74.6% patients, respectively. Approximately, 95% of patients were categorized as New York Heart Association (NYHA) class III-IV. Other important comorbidities and disease history are presented in Table 1. At baseline, patients aged ≥60 years had significantly higher HR (87.03 ± 4.53 vs. 81.31 ± 6.75, respectively, \(P<0.0001\)) and systolic blood pressure (SBP) (132.81 ± 6.55 vs. 124.74 ± 14.75 respectively, \(P=0.0014\)) compared to patients aged <60 years.

**Reduction in SBP and HR.** During the 1-year period, patients with higher SBP and HR were treated with an average metoprolol dose of 99.75 mg. Overall resting heart rate (RHR) as measured by resting electrocardiogram decreased significantly from a baseline value of 82.72 ± 6.73 to 64.86 ± 3.21 bpm at 12 months (\(P<0.0001\)). Similarly, there was a significant drop in SBP from a baseline value of 126.73 ± 13.64 to 123.35 ± 12.31 (\(P=0.0230\)) at the 1st month follow-up, followed by an increase (124.70 ± 9.67) at the 3rd month follow-up and 125.11 ± 6.67 at the 6th month follow-up. At the 12th month follow-up, SBP levels reached a stable level of 123.37 ± 6.88 mmHg (\(P=0.0067\)), which was comparable with the levels observed at the 1st month following metoprolol treatment.

Decrease in HR from baseline to 12 months was significant in patients aged <60 years (87.03 ± 4.53 vs. 65.58 ± 3.08, \(P<0.0001\)) and ≥60 years (81.31 ± 6.75 vs. 64.29 ± 6.75, \(P<0.0001\)); however, SBP levels decreased significantly only in patients aged <60 years (\(P<0.0001\)). Although at 12 months, there was greater decrease in HR and SBP in patients aged < 60 years, this group had significantly higher HR (65.58 ± 3.08 vs. 64.29 ± 6.75, \(P=0.0319\)) and similar SBP (124.74 ± 14.75 vs. 122.93 ± 6.62, \(P=0.1071\)) compared with patients aged ≥60 years.

**Improvement in cardiac performance, motor function, and QoL: a comparison.** Among the cardiac function parameters, EF decreased non-significantly from baseline to 1 and 3 months in patients aged <60 years (87.03 ± 4.53 vs. 85.38 ± 0.38, \(P=0.0791\) and 36.47% ± 5.57%; \(P=0.655\), respectively). Decrease in EF from baseline to 1 and 3 months was significant in patients aged ≥60 years (37.79% ± 5.89% to 35.25% ± 6.08%; \(P=0.014\) and 35.46% ± 4.92%; \(P<0.0001\), respectively). However, treatment with metoprolol significantly improved EF at 6 and 12 months in both the age groups (\(P<0.0001\) for change, Table 2). For cardiac index (CI), a non-significant decrease was observed from baseline to 1 month in patients aged <60 years, whereas
the decrease was significant in patients aged ≥60 years (1.79 ± 0.21 vs. 1.71 ± 0.27, P = 0.015). A similar trend of overall significant increase in CI was reported from baseline to 3, 6, and 12 months in patients aged ≥60 years (1.79 ± 0.21 vs. 2.24 ± 0.19, 2.61 ± 0.18 and 2.78 ± 0.25, P < 0.0001 for all comparisons). CI was similar for both the groups at all follow-up durations, showing similar improvement in cardiac function in elderly and patients aged <60 years after metoprolol treatment (Table 2).
Motor function evaluation with 6-minute walk test (6MWT) showed that patients in the ≥ 60- and < 60-year age groups walked similar distances at all the follow-up points. At the 1-month follow-up, patients aged ≥ 60 years had significantly higher walking distance on the 6MWT compared with patients aged < 60 years (344.51 ± 32.23 vs. 331.73 ± 32.08, P < 0.0353). However, patients aged < 60 years had non-significantly higher motor function compared with patients aged < 60 years at 12 months (416.81 ± 19.26 vs. 416.32 ± 21.35, P = 0.9002, Table 2). Within the ≥ 60-year age group, a trend of initial decrease in motor function from baseline to up to 3 months was observed; however, the motor function on 6MWT significantly increased at 6 and 12 months compared with baseline (P < 0.0001 for both comparisons, Table 2). Veterans Specific Activity Questionnaire (VSAQ) scores were similar in both the groups at all the time points, indicating no significant differences in motor function. Similar to 6MWT, a decreasing trend was seen in VSAQ scores from baseline to up to 3 months followed by a significant improvement (Table 2).

A comparison of QoL between the two groups via short form-8 questionnaire (SF-8) scales showed no significant difference in scores until 6 months; however, at the 12-month follow-up, patients aged < 60 years had significantly higher scores than those aged ≥ 60 years (52.89 ± 1.67 vs. 51.83 ± 2.26, P = 0.0086). In both the age groups, the SF-8 scores decreased initially until 3 months (P < 0.0001 for both), followed by a significant improvement at 6 and 12 months compared with baseline (P < 0.0001 for both, Table 2). Compared to baseline, a significant improvement in the Minnesota Living with Heart Failure questionnaire (MLHFQ) scores at 6 and 12 months was seen (P < 0.0001), which was preceded by worsening of QoL at 1 and 3 months. At 3 months, patients aged ≥ 60 years had significantly higher MLHFQ scores than those aged < 60 years (86.37 ± 5.09 vs. 88.55 ± 4.64, P = 0.0206), with similar scores observed at all other time points (Table 2).

Figure 2. (a) Change in HADS depression and anxiety – Depression (b) Change in HADS depression and anxiety – Anxiety (c) Change in combined CBI scores – Burnout.

Change in mental status. Among the CHF patients aged ≥ 60 years, the Hospital Anxiety and Depression Scale (HADS) depression score was higher throughout the study duration compared with patients aged < 60 years, with no significant difference in the depressive symptoms reported at any of the follow-up visits (Fig. 2a). However, the depression score worsened significantly from baseline to 1 month (P = 0.0092), 3 months (P = 0.0039), 6 months (P = 0.0023) and 12 months (P = 0.00023) in patients aged ≥ 60 years. Although the depression scores worsened in patients aged < 60 years from baseline to 1 month (P = 0.1530), 3 months (P = 0.1152), 6 months (P = 0.0832), and 12 months (P = 0.0612), the change was not significant. Figure 2b presents the HADS anxiety scores, which were consistently lower in the older patients till 6 months compared with patients aged < 60 years, with higher scores observed at 12 months. In the patients aged ≥ 60 years, HADS anxiety scores were consistent till 1 month (P = 0.9125) but decreased significantly at 3, 6, and 12 months from baseline (P < 0.0001 for all comparisons). The decrease in HADS anxiety scores in patients aged < 60 years followed a similar trend, with non-significant decrease till
1 month from baseline \( (P = 0.7372) \) followed by significant decrease at 3 \( (P = 0.0039) \), 6 \( (P = 0.0019) \), and 12 months \( (P = 0.0002) \).

Compared with patients aged <60 years, mean Copenhagen Burnout Inventory (CBI) scores in the patients aged ≥60 years was consistently and non-significantly lower at baseline to 12 months \( (P = 0.3120, P = 0.8046, P = 0.6684, P = 0.5897, \text{and } P = 0.9812 \text{ at baseline, 1, 3, 6, and 12-months, respectively} \) (Fig. 2c). Within the patient group aged ≥60 years, overall CBI scores worsened significantly at 3 \( (P = 0.0127) \), 6 \( (P = 0.0166) \), and 12 months \( (P = 0.0062) \) from baseline. On the other hand, the CBI scores increased in the patients aged <60 years; however, the increase was non-significant.

Age at baseline was not associated with greater risk of depression, i.e. patients aged ≥60 years had similar odds of experiencing depression compared with patients aged <60 years \( \text{odds ratio [OR]} 1.03, 95\% \text{confidence interval [CI]} \ 0.4960-2.1526, P = 0.93 \). However, male patients had significantly greater odds of depression compared with female patients \( \text{OR} 2.0621, 95\% \text{CI} 1.0494-4.0519, P = 0.0357 \). In the subgroup analysis, except significant greater CI in the HADS score ≥10 group versus the HADS score ≤11 group \( (P = 0.0421) \), no significant differences were observed in mean EF, CI, 6MWT, and VSAQ (Supplementary Table 1). However, a significant change in the variables within the group was seen at different time points.

Discussion

We explored the impact of metoprolol treatment on cardiac, motor, and QoL outcomes in CHF patients and reported improvement in all the aspects\(^{26}\). Since \( \beta \)-blockers are known to worsen psychological conditions, physicians must rightly choose their patients to treat CHF without deteriorating their QoL and mental status. To the best of our knowledge, this is the first study to compare the cardiac, motor, QoL, and mental/neurological outcomes in patients with CHF. An expected and significant reduction in HR was observed in both the groups from baseline to 12 months, due to the cardiodepressive action of \( \beta \)-blockers\(^{27}\). In our study, patients aged ≥60 years did not achieve significant SBP reduction, which was in consistence with previous study by Holler and Morgenstern, where the magnitude of blood pressure (BP) reduction was similar in all the groups without any age-dependent changes\(^{28}\). In our study, SBP was observed to be decreased significantly at the 1-month follow-up. However, very minor but consistent increase in SBP was observed till the 12-month follow-up. This is contrary to the previous observations in which no significant change in SBP was observed at 1 month\(^{29}\) and comparable decrease in SBP was observed after 3 months\(^{30}\). A possible reason for this slight increase in SBP in our study could be explained by correlating aging with HF. An increase in the levels of circulating catecholamines has been observed both in CHF and aged individuals along with desensitization of the \( \beta \)-adrenceptors due to decrease in their number\(^{31,32}\). Additionally, a disturbed \( \beta \)-adrenoceptor-mediated vasodilation has also been associated with aging due to hyper-expression and increased activity of G protein coupled receptor kinase (GRK2) in the vascular system with advancing age\(^{33}\).

With respect to cardiac performance, a biphasic response was observed wherein initial decrease till 1 month was followed by a significant improvement in EF and cardiac index until 12 months in both the age groups and no significant difference was seen when compared between the groups. This confirmed the non–age-dependent action of the \( \beta \)-blocker, metoprolol on both EF and CI\(^{34}\). Further evidence suggests the benefits of \( \beta \)-blocker use in CHF patients with reduced Left ventricular ejection fraction (LVEF)\(^{34}\) and preserved LVEF\(^{35}\). Similar to our findings, a study by Neto et al. reported improved EF, lowered LVEF, and cardiac frequency in patients with NYHA II-IV grade CHF\(^{36}\). \( \beta \)-blockers are also known to demonstrate improvement in cardiac index by 0.3 to 0.8 L/min*m\(^{-2}\) due to multiple mechanism\(^{37}\). In our study, the magnitude of cardiac index change was 0.99 L/min*m\(^{-2}\) in patients aged ≥60 years and 0.96 L/min*m\(^{-2}\) in patients aged <60 years, showing overall a similar effect in both age groups and concordance with previous findings.

The trend of motor improvement was accompanied with a decreasing pattern in motor function in both age groups from baseline to 1 month, followed by an improvement till the end of follow-up. The decrease in 6MWT distance and VSAQ scores in this study may be correlated with decreased cardiac performance at 1 month as patients with CHF usually report myopathy of both cardiac and skeletal muscles\(^{38}\). This further validates the finding that cardiovascular diseases are associated with deteriorating motor functions\(^{39,40}\). 6MWT is a reliable measure for motor function in multiple studies which has shown a significant improvement in CHF patients\(^{41,42}\). Similar to previous findings, in the current study, 6MWT predicted a significant improvement in motor function. However, the improvement was in both groups without any significant difference among the patients of different ages. Similarly, VSAQ has been validated in Chinese patients with HF\(^{43}\) and has further shown to be associated with poor QoL on MLHFQ scores\(^{44}\). QoL in patients with CHF is significantly low due to the effect of HF on the motor functions, constant requirement for healthcare support, which is a burden for patients with lower socioeconomic status\(^{36}\). \( \beta \)-blockers, including metoprolol, however have reported a significant improvement in the QoL in CHF patients using SF-36, MLHFQ, and Quality of Life in chronic Heart Failure Questionnaire (QLQ-CHF)\(^{45,46}\). However, a recent randomized trial by Mittal et al. showed that metoprolol did not significantly improve the QoL in CHF patients using the SF-36 questionnaire\(^{47}\). In another study by Waldstein et al., metoprolol treatment significantly improved HR, cardiac function, motor function, and QoL at 12 months\(^{47}\). In our study, the trend of QoL in CHF patients after metoprolol treatment was similar to the cardiac function and motor function trend, showing an initial decline in QoL till 1 month with a subsequent improvement till 12 months. Similar trend of change in cardiac, motor function, and QoL indicated a relation between them.

Although CHF patients are susceptible for developing depression and anxiety due to neurohormonal dysregulation\(^{48}\), these symptoms are mostly underestimated leading to progression of comorbidities\(^{49}\), thereby increasing the risk of mortality\(^{50,51}\). There is mounting evidence supporting the fact that depression and anxiety are highly prevalent in elderly patients impacting their QoL\(^{52,53}\). From our previous experience, worsening of in patients with CHF, which was non-related to metoprolol, induced HR reduction but possibly due to administration of other CV drugs or due to involvement of metabolizing enzymes. Further the anxiolytic effect of metoprolol was
observed in CHF patients via RHR reduction24. In the present study, patients aged ≥60 years reported consistent and non-significant higher HADS_depression score after metoprolol treatment. This corroborates the findings that metoprolol and other β-blockers are associated with depression22,55 and the dosage and duration of treatment should be carefully monitored in all patients irrespective of their age. Owing to its direct effects on the central β-receptors26, treatment with metoprolol effectively controlled anxiety in both the groups resulting in similar HADS_anxiety scores throughout the study. Evaluation of burnout in CHF patients aged ≥60 years showed significant worsening from baseline to end of follow-up with no significant difference seen compared with the <60 year age group. Since older patients had lower burnout throughout the study and no previous findings have elucidated the difference in patients of different age groups, further studies are warranted to explore the burnout using CBI scores.

The study has some major strengths, which include (i) first study to determine the age-dependent changes in CHF patients and (ii) the study included a comprehensive evaluation of cardiac, functional, motor, and mental effects in the patients after metoprolol administration. In addition, our study also had a few limitations due to which the results must be carefully interpreted: (i) the study had only the treatment group and no placebo or active control (β-blocker effective in CHF: carvedilol or bisoprolol) group was included, presence of which could have projected the efficacy of metoprolol in a more effective manner and (ii) the subjective questionnaires could have induced a factor of bias to the findings (however, this was addressed to an extent by the provision of assistance by healthcare practitioners (HCPs) for responding to the questions); (iii) since depression and burnout in HADS_depression and CBI scores worsened, a longer follow-up could have helped in determining the extent of change depending on the duration of therapy; (iv) known history (duration, severity and any other treatments) would also yield more reliable results; and (v) the patients in the <60- and ≥60-year age groups were distributed in 1:3 proportion. Therefore, due to a small sample size of patients aged <60 years (n = 38), the conclusions drawn should be carefully extrapolated as the study might be inadequately powered. Larger randomized studies shall be performed to confirm the findings of this study.

Materials and Methods
Study design and patient population. Complete study design and criteria for including participants have been described elsewhere26. Briefly, this prospective study enrolled CHF patients (HR > 80 bpm) with or without neuropsychiatric disorders treated at The Second Affiliated Hospital of Kunming Medical University between February 2013 and April 2016. Patients were excluded if they had (i) HR < 60 bpm; (ii) SBP < 90 mmHg; (iii) history of metoprolol use in the last 3 months; (iv) <6 months of expected survival; (v) pacemaker implanted; (vi) contraindication to β-blockers; (vii) been administered class I or class III anti-arrhythmic drugs; (viii) recent heart attack; and (ix) undergone coronary bypass surgery. The study complied with Good Clinical Practices, declaration of Helsinki and its subsequent revisions. All the patients were included in the study only after obtaining a signed informed consent. All the experimental protocols were approved by The Second Affiliated Hospital of Kunming Medical University licensing committee and the study was conducted in accordance with relevant guidelines and regulations.

Treatment plan. Data collection was performed for patients with history of initial metoprolol dosing of 23.75 or 47.5 mg (Betaloc® ZOK, AstraZeneca, Sweden). The dose was subsequently increased by 23.75 mg/week until target HR of 60–70 bpm was achieved in few patients during follow-up.

Study outcomes and measurements. The study outcome was to compare cardiac function, motor function, QoL, and mental status at 1, 3, 6, and 12-months from baseline in elderly patients aged ≥60 years versus patients aged <60 years. A trend of change in all the outcomes was also evaluated within the groups.

The measurement scales and method for assessment of SBP, RHR, cardiac function (EF and CI), motor function (6MWT and VSAQ), and QoL (SF-8 and MLHFQ) are described elsewhere26. Mental assessment was performed using the HADS and CBI scale. HADS is a self-administered questionnaire, with seven questions each for depression and anxiety. Patients with HADS score 8–10 and 11–21 were considered borderline normal and abnormal, respectively27. The CBI questionnaire measures personal, work-, and client-related burnout by patients’ perspective28. Patients who experienced difficulty in completing the HADS and CBI questionnaires were assisted by the HCPs. A subgroup analysis was performed to compare the EF, CI, 6MWT, and VSAQ between patients with HADS_depression score ≥11 versus HADS_depression score ≤10 at baseline. The subgroup analysis was performed irrespective of the age of the patients.

Statistical analysis. Descriptive statistics was used to present the baseline characteristics as mean ± standard deviation (SD), median (range), numbers, and percentages. Values for EF, CI, 6MWT, VSAQ, SF-8, MLHFQ, HADS, and CBI in both age groups and genders were presented as mean ± SD. Student’s t-test was used to compare the mean values for all the parameters between the two groups. A P value of <0.05 was considered statistically significant.

Conclusion Treatment with metoprolol demonstrated an effective improvement in cardiac performance, motor function, QoL, and anxiety in patients from both the groups, whereas an increase in the depression and burnout was noted. Despite the changes within the groups, the patients belonging to both ≥60-year and <60-year age groups had similar changes after treatment, indicating the consistent efficacy of metoprolol for CHF patients irrespective of the age.
References
1. Zhu, Y., Sun, R. & Dong, E. Heart failure research in China: current status and future direction. Sci. Bull. 61, 1793–1801 (2016).
2. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62, e147–239 (2013).
3. Ramani, G. V., Uber, P. A. & Mehta, M. R. Chronic heart failure: contemporary diagnosis and management. Mayo Clin. Proc. 85, 180–195 (2010).
4. Dunlay, S. M. et al. Activities of daily living and outcomes in heart failure. Circ. Heart Fail. 8, 261–267 (2015).
5. Hopkinson, N. S. et al. Central and peripheral quadriceps fatigue in congestive heart failure. Int. J. Cardiol. 167, 2594–2599 (2013).
6. Goldstein, L. B. & El Husseini, N. Neurology and cardiology: points of contact. Rev. Esp. Cardiol. 64, 319–327 (2011).
7. Li, H. & Ge, J. Cardiovascular diseases in China: current status and future perspectives. Int. J. Cardiol. Heart Vasc. 6, 25–31 (2015).
8. Bai, Y., Anversa, P. & Ge, J. Chronic heart failure: opportunities for a bridge between China and the United States. Circ. Res. 113, 362–364 (2013).
9. Cheng, Z. et al. Poor prognosis in chronic heart failure patients with reduced ejection fraction in China. Congest. Heart Fail. Greenwichtown 18, 165–172 (2012).
10. Chan, H. Y., Yu, D. S., Leung, D. Y., Chan, A. W. & Hui, E. Quality of life and palliative care needs of elderly patients with advanced heart failure. J. Geriatr. Cardiol. 13, 420–424 (2016).
11. Santulli, G. Sympathetic Nervous System Signaling in Heart Failure and Cardiac Aging. In Pathophysiology and Pharmacotherapy of Cardiovascular Disease (eds Jagadeesh, G., Balakumar, P. & Maung-U, K.) 83–105 (Springer International Publishing), https://doi.org/10.1007/978-3-319-15961-4_5 (2015).
12. Ciccarelli, M., Sorrentino, D., Cosenzio, E., Iaccarino, G. & Santulli, G. Adrenergic Receptors. In Endocrinology of the Heart in Health and Disease 285–315 (Elsevier), https://doi.org/10.1016/B978-0-12-803111-7.00011-7 (2017).
13. Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J. Card. Fail. 16, e1–e2 (2010).
14. Manurung, D. & Trisnohadi, H. B. Beta blockers for congestive heart failure. Acta Medica Indones. 39, 44–48 (2007).
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet Lond. Engl. 353, 2001–2007 (1999).
16. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 90, 1763–1773 (1994).
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet Lond. Engl. 353, 9–13 (1999).
18. Tate, C. W. et al. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J. Card. Fail. 13, 732–737 (2007).
19. Baxter, A. J. et al. Beta blockers in older persons with heart failure: tolerability and impact on quality of life. Heart Br. Card. Soc. 88, 611–614 (2002).
20. Dobre, D., van Jaarsveld, C. H., de Jongste, M. J. I., Haaijer Ruskamp, F. M. & Ranchor, A. V. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoeconom. Drug Saf. 16, 152–159 (2007).
21. Volodgina, A. V. Effects of beta-blocker metoprolol on quality of life in elderly patients with chronic heart failure. Ration. Pharmacother. Cardiol. 3, 24–30 (2016).
22. Muzyk, A. J. & Gagliardi, J. P. Do Beta Blockers Cause Depression? Curr. Psychiatry 9, 50 (2010).
23. Iang, W. et al. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation 110, 3452–3456 (2004).
24. Tangeman, H. J. & Patterson, J. H. Extended-release metoprolol succinate in chronic heart failure. Ann. Pharmacother. 37, 701–710 (2003).
25. Wiklund, I., Waagstein, F., Swedberg, K. & Hjalmarsson, A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardiov. Drugs Ther. 10, 361–368 (1996).
26. Meng, Y., Liu, X., Liu, J. & Cheng, X. A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients. Int. J. Cardiol. 227, 267–271 (2017).
27. Ladage, D., Schwinger, R. H. G. & Brixius, K. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc. Ther. 31, 76–83 (2013).
28. Höfler, D. & Morgenstern, H. O. Age dependence of therapy result and risk in the treatment of arterial hypertension? J. Cardiovasc. Pharmacol. 16(Suppl 5), S184–188 (1990).
29. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation for left ventricular dysfunction pilot study. Circulation 101, 378–384 (2000).
30. Hara, M., Plokker, G. L. & Markham, A. Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs 59, 141–157 (2000).
31. Santulli, G. & Iaccarino, G. Adrenergic signaling in heart failure and cardiovascular aging. Maturitas 93, 65–72 (2016).
32. Santulli, G., Ciccarelli, M., Trimarco, B. & Iaccarino, G. Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the adrenergic system. Front. Physiol. 4, 209 (2013).
33. Izzo, R. et al. Enhanced GRK2 expression and desensitization of betaAR vasodilatation in hypertensive patients. Clin. Transl. Sci. 1, 215–220 (2008).
34. Chatterjee, S. et al. Benefits of ß blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346, f55 (2013).
35. Liu, F. et al. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PloS One 9, e90555 (2014).
36. De Figueiredo Neto, J. A., Mady, C. & Grupi, C. Effects of metoprolol tartrate therapy in patients with heart failure. Arq. Bras. Cardiol. 87, 329–335 (2006).
37. Metra, M. et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. 40, 1248–1258 (2002).
38. Arslan, S. et al. Prognostic value of 6-minute walk test in stable outpatients with heart failure. Tex. Heart Inst. J. 34, 166–169 (2007).
39. Yang, Y.-J., He, X.-H., Guo, H.-Y., Wang, X.-Q. & Zhu, Y. Efficiency of muscle strength training on motor function in patients with coronary artery disease: a meta-analysis. Int. J. Cardiol. Exp. Med. 8, 17536–17538 (2015).
40. Kojović, J., Milčković, N., Janković, M. M. & Popović, D. B. Recovery of motor function after stroke: a polymography-based analysis. J. Neurosci. Methods 194, 321–328 (2011).
41. Chung C. J. & Christian Schulze P. Exercise in patients with heart failure. Heart Fail. Clin. 39, 37–43 (2011).
42. Passantino, A., Lagioia, R., Mastropaques, F. & Scrutinio, D. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice. J. Am. Coll. Cardiol. 48, 99–105 (2006).
43. Kaminsky, L. A. & Tuttle, M. S. Functional assessment of heart failure patients. Heart Fail. Clin. 11, 29–36 (2015).
44. Silva, P. C. et al. Impact of physical limitation in quality health related of heart failure patients = Impacto da limitação física na qualidade de vida relacionada a saúde de pacientes com insuficiência cardíaca. Biocor. J. 33 (2017).
45. Heo, S., Lennie, T. A., Okoli, C. & Moser, D. K. Quality of life in patients with heart failure: ask the patients. Heart Lung J. Crit. Care 38, 100–108 (2009).
46. Mittal, N. et al. Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomization, double-blind, placebo-controlled pilot trial. Perspect. Clin. Res. 8, 124–131 (2017).
47. Waagstein, F. et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. *Lancet Lond. Engl.* 342, 1441–1446 (1993).

48. Chapa, D. W. et al. Pathophysiological relationships between heart failure and depression and anxiety. *Crit. Care Nurse* 34, 14–24, quiz 25 (2014).

49. Cully, J. A., Jimenez, D. E., Ledoux, T. A. & Deswal, A. Recognition and treatment of depression and anxiety symptoms in heart failure. *Prim. Care Companion J. Clin. Psychiatry* 11, 103–109 (2009).

50. Freedland, K. E., Carney, R. M. & Rich, M. W. Effect of depression on prognosis in heart failure. *Heart Fail. Clin.* 7, 11–21 (2011).

51. Vongmany, J., Hickman, L. D., Lewis, J., Newton, P. J. & Phillips, J. L. Anxiety in chronic heart failure and the risk of increased hospitalisations and mortality: A systematic review. *Eur. J. Cardiovasc. Nurs. J. Work. Group Cardiovasc. Nurs. Eur. Soc. Cardiol.* 15, 478–485 (2016).

52. Sözeri-Varma, G. Depression in the elderly: clinical features and risk factors. *Aging Dis.* 3, 465–471 (2012).

53. Hek, K. et al. Anxiety disorders and comorbid depression in community dwelling older adults. *Int. J. Methods Psychiatr. Res.* 20, 157–168 (2011).

54. Liu, X., Lou, X., Cheng, X. & Meng, Y. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. *Drug Des. Devel. Ther.* 7, 11–21 (2011).

55. Prescribing Information - TOPROL-XL®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019962s038lbl.pdf Accessed date: 15 November 2018.

56. Koella, W. P. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. *Eur. J. Clin. Pharmacol.* 28(Suppl), 55–63 (1985).

57. Hospital Anxiety and Depression Score (HADS). https://www.bgs.org.uk/sites/default/files/content/attachment/2018-07-05/hads_mood.pdf Accessed date: 15 November 2018.

58. Molinero Ruiz, E., Basart Gómez-Quintero, H. & Moncada Lluis, S. Validation of the Copenhagen Burnout Inventory to assess professional burnout in Spain. *Rev. Esp. Salud Publica* 87, 165–179 (2013).

**Author Contributions**

Y.M. and J.H. conceived the study, designed the experiments, and wrote the manuscript. Q.S. analyzed the data with the help of L.W., R.Z. and Q.Z. and performed a critical revision of the manuscript. All authors have read and approved the final manuscript.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-37520-8.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019